Cross-Border Investment: Navigating Complexity for Returns | LeverVenture

A company with operations or clinical sites in more than one jurisdiction is not one underwriting problem. It is several, and they do not resolve on the same timeline or answer to the same authority. Regulatory screening, data governance, tax structure, currency exposure, and board governance each run on their own clock, and a diligence process that treats "cross-border" as a single checklist item misses the fact that each of these can independently stall or restructure a deal.

This is a routine condition in growth-stage life sciences and healthcare, not an edge case. A therapeutics company running trial sites across North America, Europe, and Asia; a diagnostics business manufacturing in one country and commercializing in another; a digital health platform processing patient data that crosses borders as a matter of how cloud infrastructure works — each of these is, by default, a cross-border underwriting exercise, whether or not "international" appears anywhere in the pitch.

The right approach is not to treat cross-border complexity as a discount factor applied at the end of the model. It is to identify, early, which of the five dimensions below actually apply to a given company, size the real cost and timeline risk each one carries, and structure the investment to survive the ones that cannot be eliminated.

01Regulatory review and foreign investment screening

Governments in most major markets now operate some form of foreign investment screening for transactions involving sensitive technology, critical infrastructure, or personal data at scale — the CFIUS process in the United States is the most familiar example to a U.S.-based investor, and comparable mechanisms exist in the European Union, the United Kingdom, and a growing list of other jurisdictions. These regimes were built with defense and critical infrastructure in mind, but life sciences and health data assets increasingly fall within their scope, particularly where genomic data, large patient datasets, or dual-use biotechnology are involved.

The practical consequence is that a transaction's investor base, not just its target, can trigger a review. A cross-border investment involving certain foreign capital sources may require a filing, a waiting period, or in some cases divestiture conditions that were never contemplated in the original deal terms. This risk needs to be assessed at the term sheet stage, based on the specific nationality and structure of the capital involved, rather than discovered during a closing process already in motion.

02Data residency and cross-border transfer

Health data is now one of the most heavily regulated categories of information in most developed markets, and the rules governing where it may be stored and how it may move across a border vary meaningfully by jurisdiction. A platform that collects patient data in the European Union and processes it on infrastructure located elsewhere is operating inside a legal framework that treats that transfer as a distinct, regulated event — not an implementation detail.

For a growth-stage digital health or diagnostics company, this shows up as real architectural constraint, not paperwork: data residency requirements can dictate where infrastructure must physically sit, which in turn affects everything from cloud vendor selection to the cost structure of scaling into a new market. An investor should ask, specifically, where patient data is generated, where it is stored, and what legal mechanism governs any transfer between the two — and should treat a vague answer to that question as a real flag, not a formality to clear in legal diligence later.

03Withholding, treaty structure, and where the return actually lands

Cross-border investment structures determine not just how much a company owes in tax, but how much of an investor's return actually reaches the investor after withholding at the source. Dividends, interest, and in some structures capital gains can be subject to withholding tax in the jurisdiction where the underlying company operates, and the rate that applies depends heavily on whether a tax treaty exists between that jurisdiction and the investor's own, and on whether the investment structure is built to actually qualify for that treaty's reduced rate.

This is a structuring exercise that belongs at the front of a transaction, not a cleanup task for after closing. The choice of holding company jurisdiction, the legal form of the investment vehicle, and the specific treaty relationships in play can change realized after-tax returns by a meaningful margin, and getting this wrong is expensive precisely because it is difficult to fix retroactively once capital has already moved.

04Currency exposure and the hedging decision

A growth investment denominated in one currency, into a company earning revenue in another, carries currency risk that is entirely independent of how well the business performs. A company can hit every operating target it set and still deliver a disappointing return in the investor's home currency if the exchange rate has moved against it over the hold period, and that risk is often concentrated precisely at the moment it matters most — conversion of proceeds at exit.

Hedging that exposure is not free, and over a multi-year growth-equity hold period, the cost and practicality of maintaining a hedge shift as the company's scale and geography evolve. The decision is not simply "hedge or don't." It requires deciding which portion of the exposure is worth the ongoing cost to hedge, which portion is small enough to simply accept, and revisiting that judgment as the company's revenue mix across currencies changes with growth.

A business can execute perfectly and still return less than underwritten, for reasons that have nothing to do with the business. That gap belongs in the model, not in the surprise column.

05Governance and enforcement across legal systems

Minority protections that look identical on paper — board seats, information rights, veto rights over major decisions — can mean materially different things depending on which jurisdiction's courts would actually enforce them. A protective provision governed by a legal system with a slow or uncertain enforcement track record for minority shareholder rights is a weaker protection than the same clause governed by a system with a well-established record of enforcing them, even though the contract language may be word-for-word identical.

This matters most in exactly the situation an investor hopes never to face: a board deadlock, a dispute with a founder or co-investor, or an attempt to exercise a protective right against the company's wishes. Diligence on governing law and dispute resolution mechanism deserves the same rigor as diligence on the financial terms themselves, because a right that cannot be practically enforced is, functionally, not a right.

06Underwriting a company that spans borders

The discipline that works is treating each of these five dimensions as a separate diligence track with its own owner, its own timeline, and its own go/no-go criteria, rather than folding them into a single generic "international risk" line. A therapeutics company with trial sites in three regions needs regulatory and data-residency diligence specific to each one. A structure involving investors from a sensitive jurisdiction needs a foreign investment screening assessment before term sheet, not after. A multi-currency revenue base needs an explicit, revisited hedging policy, not a one-time decision made at close and forgotten.

None of this is a reason to avoid cross-border opportunities in life sciences and healthcare — some of the most interesting growth-stage companies in the sector are, by nature, global from an early stage. It is a reason to underwrite the jurisdictional complexity with the same rigor applied to the clinical or commercial thesis, because a company can be right about the medicine and still deliver a disappointing outcome to its investors for reasons that were fully knowable in diligence and simply were not priced.

For how this complexity interacts with a company's eventual buyer pool, see why the middle market's exit set is structurally wider, and for the related funding-timeline pressures a global clinical footprint creates, see the funding window biotech companies face after an IPO.

Nothing in this piece is investment, legal, tax or accounting advice, and nothing in it is an offer to sell or a solicitation of an offer to buy any security.